Equities

Aurobindo Pharma Ltd

AUROPHARMA:NSI

Aurobindo Pharma Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,528.10
  • Today's Change-7.90 / -0.51%
  • Shares traded692.59k
  • 1 Year change+70.80%
  • Beta0.8892
Data delayed at least 15 minutes, as of Sep 19 2024 11:17 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
OPERATIONS
Net income43,80026,12533,727
Depreciation/depletion15,21712,44611,265
Non-Cash items(254)3,4192,176
Cash taxes paid, supplemental17,6667,17212,582
Cash interest paid, supplemental2,5071,112185
Changes in working capital(34417)(18058)2,964
Total cash from operations24,34523,93250,132
INVESTING
Capital expenditures(35615)(27204)(27046)
Other investing and cash flow items, total(6945)(12574)(5069)
Total cash from investing(42560)(39778)(32116)
FINANCING
Financing cash flow items(2507)(1112)(185)
Total cash dividends paid(2636)(4395)(2637)
Issuance (retirement) of stock, net------
Issuance (retirement) of debt, net13,14723,651(26871)
Total cash from financing8,00418,144(29693)
NET CHANGE IN CASH
Foreign exchange effects142(0.6)2.00
Net change in cash(10068)2,298(11674)
Net cash-begin balance/reserved for future use43,92341,62553,299
Net cash-end balance/reserved for future use33,85443,92341,625
SUPPLEMENTAL INCOME
Depreciation, supplemental15,21712,44611,265
Cash interest paid, supplemental2,5071,112185
Cash taxes paid, supplemental17,6667,17212,582
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.